TG Therapeutics
TGTX Mid CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
TG Therapeutics en bref
TG Therapeutics (TGTX) is currently trading at 46,40 € with a market capitalization of 7,1 Md €. The trailing P/E ratio stands at 18.61x, with a forward P/E of 18.53x. The 52-week range spans from 22,04 € to 47,14 €; the current price is 1.6% below the yearly high. Year-over-year revenue growth stands at +69.6%. The net profit margin stands at 65.95%.
💰 Dividende
TG Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
7 analystes évaluent TG Therapeutics (TGTX) au consensus : Acheter. L'objectif de cours moyen est de 41,84 €, soit un potentiel de -9.81% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 14,82 € à 61,02 €.
TG Therapeutics : la thèse d'investissement en détail
TG Therapeutics (TGTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 69.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 83.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 112.6% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
Le scénario baissier
Short interest sits at 26.61% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
The EV/EBITDA multiple of 49.48x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The share is trading at 97% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 69.6% sur un an
- Rentable avec une marge nette de 65.95%
- Rentabilité élevée des capitaux propres (112.6% ROE)
- Marge brute élevée de 83.05% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- –Positions vendeuses élevées (26.61%)
- –Free cash flow négatif
- –Cours proche du plus haut 52 semaines — faible marge de hausse
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to above-average price swings, elevated short interest (26.61%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy TG Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news